Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury
Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury
复制标题
DOI：
10.1046/j.1460-9568.2003.02875.x
复制
发表时间：
2003-09-01
影响因子：
3.4
通讯作者：
Myers, RR
中科院分区：
文献类型：
--
作者：
Campana, WM;Myers, RR
促红细胞生成素（Epo）在缺血性损伤的动物模型中已被证明在中枢神经系统神经元中具有有效的抗凋亡活性。最近，已经在外周神经系统中鉴定了Epo及其受体（EpoR）[Campana & Myers（2001），FASEB J.，15，1804-1806]。在此，我们证明，在由L5脊神经挤压（SNC）引起的疼痛性神经病变中，用重组人Epo（rhEpo）治疗减少背根神经节（DRG）凋亡和疼痛行为。DRG神经元和卫星细胞的定量显示，与rhEpo处理的挤压损伤的DRG中7.5 +/-6.3%的凋亡神经元和6.4 +/-3.94%的卫星细胞相比，载体处理的挤压损伤的DRG具有35.5 +/-8.3%的凋亡神经元和23.5 +/-2.36%的卫星细胞（P< 0.05）。虽然rhEpo治疗的动物最初没有受到与L5 SNC相关的机械性异常性疼痛的保护，但与载体治疗的动物相比，rhEpo确实显著提高了恢复率（P
Erythropoietin (Epo) has been shown to have potent anti-apoptotic activity in central nervous system neurons in animal models of ischaemic injury. Recently, Epo and its receptor (EpoR) have been identified in the peripheral nervous system [Campana & Myers (2001), FASEB J., 15, 1804-1806]. Herein, we demonstrate that in painful neuropathy caused by L5 spinal nerve crush (SNC), therapy with recombinant human Epo (rhEpo) reduced dorsal root ganglion (DRG) apoptosis and pain behaviours. Quantification of both DRG neurons and satellite cells revealed that vehicle-treated, crush-injured DRGs had 35.5 +/- 8.3% apoptotic neurons and 23.5 +/- 2.36% satellite cells compared with 7.5 +/- 6.3% apoptotic neurons and 6.4 +/- 3.94% satellite cells in rhEpo-treated, crush-injured DRGs (P< 0.05). While rhEpo-treated animals were not initially protected from mechanical allodynia associated with L5 SNC, rhEpo did significantly improve recovery rates compared to vehicle-treated animals (P